| Biomarker ID | 1333 |
| PMID | 24518785 |
| Year | 2014 |
| Biomarker | U78_x; SNORD78; U78_s; miR-182; U17b; miR-22; miR-34a*; miR-221*; miR-187; miR-221; miR-34c-3p; |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa: U78_x (3.8 fold); SNORD78 (3.6-fold); U78_s (3.7-fold); miR-182 (4.7-fold); U17b (2.7- fold)Downregulated in PCa: miR-224 (4.05-fold); miR-34a* (3-fold); miR-221* (3.3-fold); miR-187 (12-fold); miR-221 (2.2-fold); miR-34c-3p (1.7-fold) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include: synapse; presynapse; cell junction; generation of neurons; neurogenesis Pathways Include(miR-22):- cell development; nucleoplasm; synapse; nervous system development; neurogenesis Pathways Include(miR-221):-homophilic cell adhesion via plasma membrane adhesion molecules; transcription by RNA polymerase II; regulation of transcription by RNA polymerase II; DNA binding; synapse |
| Experiment | Prostate Cancer Vs Normal Prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 10 normal prostate and 50 prostate cancer samples were selected for the analysis. GEO Accession: GSE45604 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | U78_x, SNORD78, U78_s, miR-182, U17b, miR-22, miR-34a*, miR-221*, miR-187, miR-221, miR-34c-3p |